Daniel J. Hodson
YOU?
Author Swipe
View article: Efficacy and Safety of Capivasertib (AZD5363), a Potent, Oral Pan-AKT Inhibitor, in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (CAPITAL)
Efficacy and Safety of Capivasertib (AZD5363), a Potent, Oral Pan-AKT Inhibitor, in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (CAPITAL) Open
Purpose: An unmet treatment need remains for relapsed/refractory (R/R) non-Hodgkin lymphoma (NHL), including the follicular lymphoma (FL), mantle cell lymphoma (MCL), and marginal zone lymphoma (MZL) subtypes. The PI3K/AKT/mTOR pathway is …
View article: No increase in incidence of central nervous system (CNS) relapse after removal of cns prophylaxis in large B cell lymphoma: A real-world retrospective study.
No increase in incidence of central nervous system (CNS) relapse after removal of cns prophylaxis in large B cell lymphoma: A real-world retrospective study. Open
The publication of studies demonstrating significant uncertainty in the efficacy of central nervous system (CNS) prophylaxis in large B-cell lymphomas (LBCL) has led to a change in UK guidelines (Wilson et al, BJHaem, 2024). The East of En…
View article: Enforced MYC expression directs a distinct transcriptional state during plasma cell differentiation
Enforced MYC expression directs a distinct transcriptional state during plasma cell differentiation Open
MYC provides a rheostat linking cell growth and division. Deregulation of MYC drives transformation in aggressive B-cell neoplasms, often accompanied by BCL2-mediated apoptotic protection. We assess how MYC and BCL2 deregulation impacts on…
View article: Strategies for CRISPR-based knock-ins in primary human B cells and lymphoma cell lines
Strategies for CRISPR-based knock-ins in primary human B cells and lymphoma cell lines Open
Since its advent about ten years ago, the CRISPR-Cas9 system has been frequently used in biomedical applications. It has advanced various fields, and CRISPR-Cas9-based therapeutics have shown promising results in the treatment of specific …
View article: The DIRECT study: A roadmap for ctDNA-based risk prediction, molecular profiling and MRD detection in Diffuse Large B Cell Lymphoma
The DIRECT study: A roadmap for ctDNA-based risk prediction, molecular profiling and MRD detection in Diffuse Large B Cell Lymphoma Open
DIRECT was a prospective, multisite study assessing the feasibility and utility of circulating tumor DNA (ctDNA) in 188 patients with aggressive B-cell non-Hodgkin lymphoma using a lymphoma-customized assay and open-source pipeline. CtDNA …
View article: Audit of B-cell cancer genes
Audit of B-cell cancer genes Open
Comprehensive genetic analysis of tumors with exome or whole-genome sequencing has enabled the identification of the genes that are recurrently mutated in cancer. This has stimulated a series of exciting advances over the past 15 years, gu…
View article: RNA-binding proteins control the G2-M checkpoint of the germinal centre B cell
RNA-binding proteins control the G2-M checkpoint of the germinal centre B cell Open
How germinal centre (GC) B cells undergo rapid cell division while maintaining genome stability is poorly understood. Here, we show that the RNA-binding proteins ZFP36L1 and ZFP36L2 act downstream of antigen-sensing and protect GC B cells …
View article: Evolving molecular classification of aggressive B‐cell lymphoma
Evolving molecular classification of aggressive B‐cell lymphoma Open
This review aims to provide an overview of the latest developments in the classification and molecular understanding of aggressive B‐cell lymphomas, specifically focusing on diffuse large B‐cell lymphoma (DLBCL) and high‐grade B‐cell lymph…
View article: Pathogenesis and Clinical Relevance of Diffuse Large B-Cell Lymphoma Proteogenotypes
Pathogenesis and Clinical Relevance of Diffuse Large B-Cell Lymphoma Proteogenotypes Open
Diffuse large B-cell lymphomas (DLBCL) are genetically and clinically heterogenous. Despite advances in the gene-expression and genomic characterization, the pathophysiology of high-risk DLBCL still remains incompletely understood. We repo…
View article: A Randomized Phase II Study of Mosunetuzumab SC Plus Polatuzumab Vedotin Demonstrates Improved Outcomes Versus Rituximab Plus Polatuzumab Vedotin in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL)
A Randomized Phase II Study of Mosunetuzumab SC Plus Polatuzumab Vedotin Demonstrates Improved Outcomes Versus Rituximab Plus Polatuzumab Vedotin in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL) Open
Background: The ongoing Phase Ib/II study (NCT03671018) evaluates mosunetuzumab (Mosun) plus polatuzumab vedotin (Pola; M-Pola) in pts with R/R LBCL. The Phase II single-arm expansion cohort showed a manageable safety profile and highly du…
View article: Supplementary Figure S14 from Molecular Determinants of Sensitivity to Polatuzumab Vedotin in Diffuse Large B-Cell Lymphoma
Supplementary Figure S14 from Molecular Determinants of Sensitivity to Polatuzumab Vedotin in Diffuse Large B-Cell Lymphoma Open
Inhibition of neddylation increases expression of BCR subunits
View article: Supplementary Figure S9 from Molecular Determinants of Sensitivity to Polatuzumab Vedotin in Diffuse Large B-Cell Lymphoma
Supplementary Figure S9 from Molecular Determinants of Sensitivity to Polatuzumab Vedotin in Diffuse Large B-Cell Lymphoma Open
Mutation of CD79A and CD79B glycosylated residues does not alter sensitivity to MMAE
View article: Supplementary Table 1 from Molecular Determinants of Sensitivity to Polatuzumab Vedotin in Diffuse Large B-Cell Lymphoma
Supplementary Table 1 from Molecular Determinants of Sensitivity to Polatuzumab Vedotin in Diffuse Large B-Cell Lymphoma Open
CRISPR Screen Scores
View article: Supplementary Figure S10 from Molecular Determinants of Sensitivity to Polatuzumab Vedotin in Diffuse Large B-Cell Lymphoma
Supplementary Figure S10 from Molecular Determinants of Sensitivity to Polatuzumab Vedotin in Diffuse Large B-Cell Lymphoma Open
KLHL6 loss does not score as a negative regulator of surface CD79B or Pola-V sensitivity in CRISPR screens of ABC DLBCL cell lines and KLHL6 loss does not sensitize to MMAE
View article: Supplementary Figure S2 from Molecular Determinants of Sensitivity to Polatuzumab Vedotin in Diffuse Large B-Cell Lymphoma
Supplementary Figure S2 from Molecular Determinants of Sensitivity to Polatuzumab Vedotin in Diffuse Large B-Cell Lymphoma Open
Knockout of SLC35A1, SLC35A2, and ST6GAL1 decreases surface a2,6-linked sialic acid.
View article: Supplementary Table 2 from Molecular Determinants of Sensitivity to Polatuzumab Vedotin in Diffuse Large B-Cell Lymphoma
Supplementary Table 2 from Molecular Determinants of Sensitivity to Polatuzumab Vedotin in Diffuse Large B-Cell Lymphoma Open
Glycoproteomics
View article: Supplementary Figure S9 from Molecular Determinants of Sensitivity to Polatuzumab Vedotin in Diffuse Large B-Cell Lymphoma
Supplementary Figure S9 from Molecular Determinants of Sensitivity to Polatuzumab Vedotin in Diffuse Large B-Cell Lymphoma Open
Mutation of CD79A and CD79B glycosylated residues does not alter sensitivity to MMAE
View article: Supplementary Table 3 from Molecular Determinants of Sensitivity to Polatuzumab Vedotin in Diffuse Large B-Cell Lymphoma
Supplementary Table 3 from Molecular Determinants of Sensitivity to Polatuzumab Vedotin in Diffuse Large B-Cell Lymphoma Open
KLHL6 proteomics
View article: Supplementary Figure S13 from Molecular Determinants of Sensitivity to Polatuzumab Vedotin in Diffuse Large B-Cell Lymphoma
Supplementary Figure S13 from Molecular Determinants of Sensitivity to Polatuzumab Vedotin in Diffuse Large B-Cell Lymphoma Open
DLBCL mutations targeting the CD79B intracellular domain and their effect on surface BCR levels
View article: Supplementary Figure S4 from Molecular Determinants of Sensitivity to Polatuzumab Vedotin in Diffuse Large B-Cell Lymphoma
Supplementary Figure S4 from Molecular Determinants of Sensitivity to Polatuzumab Vedotin in Diffuse Large B-Cell Lymphoma Open
SLC35A2 targeted degradation by dTag modification synergizes with Pola-V.
View article: Supplementary Figure S11 from Molecular Determinants of Sensitivity to Polatuzumab Vedotin in Diffuse Large B-Cell Lymphoma
Supplementary Figure S11 from Molecular Determinants of Sensitivity to Polatuzumab Vedotin in Diffuse Large B-Cell Lymphoma Open
Knockout of the E3 ligase KLHL6 results in increased cell surface CD79B in a human model of GCB DLBCL
View article: Supplementary Figure S5 from Molecular Determinants of Sensitivity to Polatuzumab Vedotin in Diffuse Large B-Cell Lymphoma
Supplementary Figure S5 from Molecular Determinants of Sensitivity to Polatuzumab Vedotin in Diffuse Large B-Cell Lymphoma Open
CD79B immunohistochemistry is not predictive of Pola-V sensitivity
View article: Supplementary Table 1 from Molecular Determinants of Sensitivity to Polatuzumab Vedotin in Diffuse Large B-Cell Lymphoma
Supplementary Table 1 from Molecular Determinants of Sensitivity to Polatuzumab Vedotin in Diffuse Large B-Cell Lymphoma Open
CRISPR Screen Scores
View article: Supplementary Figure S14 from Molecular Determinants of Sensitivity to Polatuzumab Vedotin in Diffuse Large B-Cell Lymphoma
Supplementary Figure S14 from Molecular Determinants of Sensitivity to Polatuzumab Vedotin in Diffuse Large B-Cell Lymphoma Open
Inhibition of neddylation increases expression of BCR subunits